The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
Open accessAbstract
The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years. Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward identifying a second generation of much more specific steroidal MRAs were all based on the initial 17-spirolactone construct. The salient example is eplerenone, first described in 1987, coincidentally with the cloning of MR cDNA. Its launch on the market in 2003 paralleled intensive drug discovery programs for a new generation of non-steroidal MRAs. Now, 30 years after the cDNA cloning of MR and 60 years of clinical use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease. Finerenone has already been studied in over 2000 patients with heart failure plus chronic kidney disease and/or diabetes, and in patients with diabetic kidney disease, in five phase II clinical trials. Here, we reflect on the history of the various generations of MRAs and review characteristics of the most important steroidal and non-steroidal MRAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
THE GENERAL ADAPTATION SYNDROME AND THE DISEASES OF ADAPTATION1
SELYE, H. (1946) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-6-2-117 · Cited by 2,287
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationActivating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy
Geller, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., Tsai, F. T. F., Sigler, P. B., & Lifton, R. P. (2000) · Science · doi:10.1126/science.289.5476.119 · Cited by 675
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht187 · Cited by 591
Self-citationFilippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citationKolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
Self-citationEplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Efficacy and tolerance of spironolactone in essential hypertension
Jeunemaitre, X., Chatellier, G., Kreft-Jais, C., Charru, A., Devries, C., Plouin, P.-F., Corvol, P., & Menard, J. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91030-7 · Cited by 276
Bärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 270
Self-citationINHIBITION OF THE SODIUM-RETAINING INFLUENCE OF ALDOSTERONE BY PROGESTERONE*†
LANDAU, R. L., & LUGIBIHL, K. (1958) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-18-11-1237 · Cited by 262
Antiandrogenic Effect of Spirolactones: Mechanism of Action
CORVOL, P., MICHAUD, A., MENARD, J., FREIFELD, M., & MAHOUDEAU, J. (1975) · Endocrinology · doi:10.1210/endo-97-1-52 · Cited by 259
Action of New Steroids in Blocking Effects of Aldosterone and Deoxycorticosterone on Salt
Kagawa, C. M., Cella, J. A., & Van Arman, C. G. (1957) · Science · doi:10.1126/science.126.3281.1015 · Cited by 256
Subcellular mechanisms in the action of adrenal steroids
Feldman, D., Funder, J. W., & Edelman, I. S. (1972) · The American Journal of Medicine · doi:10.1016/0002-9343(72)90152-0 · Cited by 249
Mineralocorticoid Receptors: Distribution and Activation
Funder, J. W. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2344-2 · Cited by 229
Amazit, L., Le Billan, F., Kolkhof, P., Lamribet, K., Viengchareun, S., Fay, M. R., Khan, J. A., Hillisch, A., Lombès, M., Rafestin-Oblin, M.-E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657957 · Cited by 196
Self-citationSica, D. A. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2345-1 · Cited by 192
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., Rafestin-Oblin, M.-E., & Kolkhof, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131342 · Cited by 191
Self-citationThe evolution of aldosterone antagonists
Garthwaite, S. M., & McMahon, E. G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.005 · Cited by 189
THE METABOLIC EFFECTS OF PROGESTERONE IN MAN*†
LANDAU, R. L., BERGENSTAL, D. M., LUGIBIHL, K., & KASCHT, M. (1955) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-15-10-1194 · Cited by 189
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Self-citationMolecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Kolkhof, P., & Borden, S. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.025 · Cited by 171
Self-citationSodium Diuresis Induced by Steroidal Antagonists of Aldosterone
Liddle, G. W. (1957) · Science · doi:10.1126/science.126.3281.1016 · Cited by 160
VASCULAR TYPE I ALDOSTERONE BINDING SITES ARE PHYSIOLOGICAL MINERALOCORTICOID RECEPTORS
Funder, J. W., Pearce, P., Smith, R., & Campbell, J. H. (1989) · Endocrinology · doi:10.1210/endo-125-4-2224 · Cited by 144
Arai, K., Homma, T., Morikawa, Y., Ubukata, N., Tsuruoka, H., Aoki, K., Ishikawa, H., Mizuno, M., & Sada, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.015 · Cited by 140
Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites
Gardiner, P., Schrode, K. B., Quinlan, D., Martin, B. K., Boreham, D. R., Rogers, M. S., Stubbs, K., Smith, M. E., & Karim, A. (1989) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1989.tb03339.x · Cited by 133
HIGH AFFINITY ALDOSTERONE BINDING SITES (TYPE I RECEPTORS) IN RAT HEART
Pearce, P., & Funder, J. W. (1987) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1987.tb02422.x · Cited by 130
Nonsteroidal antagonists of the mineralocorticoid receptor
Kolkhof, P., Nowack, C., & Eitner, F. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000147 · Cited by 129
Self-citationDrospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity
Muhn, P., Krattenmacher, R., Beier, S., Elger, W. A. G., & Schillinger, E. (1995) · Contraception · doi:10.1016/0010-7824(94)00015-o · Cited by 128
Specific aldosterone binding in rat kidney and parotid
Funder, J. W., Feldman, D., & Edelman, I. S. (1972) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(72)90052-0 · Cited by 128
Svensson, M., Gustafsson, F., Galatius, S., Hildebrandt, P. R., & Atar, D. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.10.012 · Cited by 120
THE EFFECT OF SEX HORMONES ON THE RENAL EXCRETION OF ELECTROLYTES
Thorn, G. W., & Engel, L. L. (1938) · The Journal of Experimental Medicine · doi:10.1084/jem.68.3.299 · Cited by 119
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
Ménard, J. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.008 · Cited by 111
Liddle, G. W. (1958) · Archives of Internal Medicine · doi:10.1001/archinte.1958.00260230144018 · Cited by 111
PHARMACOKINETICS AND METABOLISM OF [14C]EPLERENONE AFTER ORAL ADMINISTRATION TO HUMANS
Cook, C. S., Berry, L., Bible, R. H., Hribar, J. D., Hajdu, E., & Liu, N. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1448 · Cited by 107
Spironolactone: Disposition, Metabolism, Pharmacodynamics, and Bioavailability
Karim, A. (1978) · Drug Metabolism Reviews · doi:10.3109/03602537808993782 · Cited by 102
Funder, J. W., Feldman, D. I., Highland, E., et al. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90386-4 · Cited by 101
Grune, J., Benz, V., Brix, S., Salatzki, J., Blumrich, A., Hoeft, B., Klopfleisch, R., Foryst‐Ludwig, A., Kolkhof, P., & Kintscher, U. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000366 · Cited by 98
Self-citationCentral mineralocorticoid receptor antagonism blocks hypertension in Dahl S/JR rats
Gómez-Sánchez, E. P., Fort, C., & Thwaites, D. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.262.1.e96 · Cited by 94
Pitt, B., Filippatos, G. S., Gheorghiade, M., Køber, L., Krum, H., Ponikowski, P. P., Nowack, C., Kolkhof, P., Kim, S., & Zannad, F. M. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs061 · Cited by 92
Self-citationBramlage, P., Swift, S. L., Thoenes, M., Minguet, J., Ferrero, C., & Schmieder, R. E. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.444 · Cited by 92
Liu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 91
Mechanism of the antimineralocorticoid effects of spirolactones
Corvol, P. L., Claire, M., Rafestin-Oblin, M. E., Geering, K., & Rossier, B. C. (1981) · Kidney International · doi:10.1038/ki.1981.97 · Cited by 88
Arai, K., Tsuruoka, H., & Homma, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.028 · Cited by 87
Cella, J. A., & Kagawa, C. M. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01574a058 · Cited by 80
Steroidal Aldosterone Blockers. II1
Cella, J. A., & Tweit, R. C. (1959) · The Journal of Organic Chemistry · doi:10.1021/jo01090a019 · Cited by 75
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Yang, J., & Young, M. J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.005 · Cited by 65
Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?
Gómez-Sánchez, E. P. (2015) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000329 · Cited by 63
Arai, K., Morikawa, Y., Ubukata, N., Tsuruoka, H., & Homma, T. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.234765 · Cited by 62
Progestogens with antimineralocorticoid activity.
Losert, W., CASALS‐STENZEL, J., & Buse, M. (1985) · PubMed · Cited by 60
Production of Nephrosclerosis by Overdosage with Desoxycorticosterone Acetate.
Selye, H. (1942) · PubMed · Cited by 57
Protection by a Steroid-Spirolactone Against Certain Types of Cardiac Necroses.
Selye, H. (1960) · Experimental Biology and Medicine · doi:10.3181/00379727-104-25782 · Cited by 54
Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists
Arhancet, G. B., Woodard, S. S., Iyanar, K., Case, B. L., Woerndle, R. S., Dietz, J. D., Garland, D. J., Collins, J. T., Payne, M., Blinn, J. R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100506y · Cited by 50
Haller, H. G., Bertram, A., Stahl, K., & Menne, J. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0649-2 · Cited by 42
Molecular Mechanisms of Mineralocorticoid Receptor Antagonism by Eplerenone
Hu, X. J., Li, S., McMahon, E. L., et al. (2005) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557054553811 · Cited by 41
Anticortisol Action of Aldosterone
Selye, H. (1955) · Science · doi:10.1126/science.121.3141.368 · Cited by 37
Mechanism of Action of a New Antialdosterone Compound, Prorenone*
Claire, M., Rafestin-Oblin, M. E., Michaud, A., et al. (1979) · Endocrinology · doi:10.1210/endo-104-4-1194 · Cited by 37
Cook, C. S., Hauswald, C. L., Schoenhard, G. L., Piper, C. E., Patel, A. B., Radzialowski, F. M., Hribar, J. D., Aksamit, W., Finnegan, P., Bible, R. H., et al. (1988) · Archives of Toxicology · doi:10.1007/bf00316635 · Cited by 32
Dinsdale, C., Wani, M., Steward, J., & O'Mahony, M. S. (2005) · Age and Ageing · doi:10.1093/ageing/afi104 · Cited by 29
Synthesis and activities of anti-aldosterones
Laurent, H., BITTLER, D., Hofmeister, H., Nickisch, K. J., Nickolson, R. C., Petzoldt, K., & Wiechert, R. (1983) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(83)90010-9 · Cited by 22
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Bomback, A. S., Kshirsagar, A. V., & Klemmer, P. J. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph1004 · Cited by 22
Binding of Spirolactones to Human Plasma Proteins
Chien, Y. W., Hofmann, L. M., Lambert, H. J., & Tao, L. C. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650919 · Cited by 14
Finerenone in heart failure: walking a fine line
Naegele, M., Hernandez, A. F., & Ruschitzka, F. T. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw155 · Cited by 12
Hyperkalemic Cardiac Arrhythmia Secondary to Spironolactone
Pongpaew, C., Songkhla, R. N., & Kozam, R. L. (1973) · CHEST Journal · doi:10.1378/chest.63.6.1023 · Cited by 9
Cited by
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Self-citationGrune, J., Beyhoff, N., Smeir, E., Chudek, R., Blumrich, A., Ban, Z., Brix, S., Betz, I. R., Schupp, M., Foryst-Ludwig, A., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10360 · Cited by 292
Self-citationMineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Vaduganathan, M., Filippatos, G., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A., Brinker, M., Kolkhof, P., Schloemer, P., Lay-Flurrie, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03264-4 · Cited by 158
Self-citationAgarwal, R., Anker, S. D., Bakris, G., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L., Gebel, M., Kolkhof, P., Nowack, C., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa294 · Cited by 103
Self-citation
Metadata
- Authors
- Kolkhof, P., & Bärfacker, L.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2017-07
- Volume
- 234
- Issue
- 1
- Pages
- T125-T140
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2646586965
- Cited by
- 262
- References
- 72
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.